<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023980</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-BTK-20023</org_study_id>
    <secondary_id>J2N-OX-JZNP</secondary_id>
    <nct_id>NCT05023980</nct_id>
  </id_info>
  <brief_title>A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)</brief_title>
  <acronym>BRUIN CLL-313</acronym>
  <official_title>A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305;&#xD;
      Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated.&#xD;
      Participation could last up to five years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized 1:1 into Arm A and Arm B. Patients randomized to Arm B who have disease progression (PD) confirmed by independent review committee (IRC) may be eligible to crossover into Arm A.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Assessed by blinded independent review committee (IRC) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Response Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B: Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Assessments of effectiveness include PFS, assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B: Overall survival (OS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Assessments of effectiveness include OS, assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B: Time to next treatment (TTNT)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Assessments of effectiveness include TTNT, assessed by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B: Overall response rate (ORR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Assessments of effectiveness include ORR, assessed by investigator and IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B: Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Assessments of effectiveness include DOR, assessed by investigator and IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B in patient-reported disease-related symptoms</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Based on time to worsening of CLL/SLL-related symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of Arm A compared to Arm B in patient-reported physical functioning</measure>
    <time_frame>Up to approximately 5 years</time_frame>
    <description>Based on time to worsening of physical functioning</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (Pirtobrutinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirtobrutinib administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (BR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bendamustine plus rituximab administered intravenously (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirtobrutinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Arm A (Pirtobrutinib)</arm_group_label>
    <other_name>LOXO-305</other_name>
    <other_name>LY3527727</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>IV</description>
    <arm_group_label>Arm B (BR)</arm_group_label>
    <other_name>Treanda</other_name>
    <other_name>Treakisym</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>Levact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>IV</description>
    <arm_group_label>Arm B (BR)</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
    <other_name>Truxima</other_name>
    <other_name>Riabni</other_name>
    <other_name>Ruxience</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of CLL/SLL requiring therapy, per iwCLL 2018 criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Platelets greater than or equal to (≥)75 x 10⁹/liter (L) (≥50 × 10⁹/L for patients&#xD;
             with evidence of bone marrow infiltrate), hemoglobin ≥8 grams/deciliter (g/dL), and&#xD;
             absolute neutrophil count ≥0.75 x 10⁹/L&#xD;
&#xD;
          -  Kidney function: Estimated creatinine clearance ≥40 milliliters per minute (mL/min)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected Richter's transformation at any time preceding enrollment&#xD;
&#xD;
          -  Prior systemic therapy for CLL/SLL&#xD;
&#xD;
          -  Presence of 17p deletion&#xD;
&#xD;
          -  Central nervous system (CNS) involvement&#xD;
&#xD;
          -  Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA],&#xD;
             idiopathic thrombocytopenic purpura [ITP])&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C&#xD;
&#xD;
          -  Active cytomegalovirus (CMV) infection&#xD;
&#xD;
          -  Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection, regardless of cluster of&#xD;
             differentiation 4 (CD4) count&#xD;
&#xD;
          -  Concurrent use of investigational agent or anticancer therapy except hormonal therapy&#xD;
&#xD;
          -  Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K&#xD;
             antagonist&#xD;
&#xD;
          -  Vaccination with a live vaccine within 28 days prior to randomization&#xD;
&#xD;
          -  Patients with the following hypersensitivity:&#xD;
&#xD;
               -  Known hypersensitivity, including anaphylaxis, to any component or excipient of&#xD;
                  pirtobrutinib or bendamustine&#xD;
&#xD;
               -  Prior significant hypersensitivity to rituximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Safi Shahda</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-LOXO-305</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukui Medical University Hospital</name>
      <address>
        <city>Yoshida-Gun</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BTKi</keyword>
  <keyword>BTK Inhibitor</keyword>
  <keyword>Hematologic Disease</keyword>
  <keyword>Lymphoma, non-Hodgkin's</keyword>
  <keyword>Lymphoma, B-cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

